Morningstar

ClearNote Health’s Avantect® Pancreatic Cancer Test Now Available to Health Plan Members Accessing Claritev’s National PPO Networks | Morningstar

Latest agreement expands access to the PHCS and MultiPlan Networks ClearNote Health, a company focused on improving early detection for some of the deadliest cancers, today announced an agreement with ...
Morningstar

ClearNote Health Receives In Vitro Diagnostic Approval in United Kingdom for Avantect® Multi-Cancer Detection Test and Avantect® Ovarian Cancer Test | Morningstar

ClearNote Health Receives In Vitro Diagnostic Approval in United Kingdom for Avantect® Multi-Cancer Detection Test and Avantect® Ovarian Cancer Test ClearNote Health, a company focused on improving ...
MarketWatch

ClearNote Health's Avantect(R) Multi-Cancer Detection Test Selected as One of Two Noninvasive Blood-Based Technologies for National Cancer Institute's Vanguard Study

ClearNote Health, a company focused on improving early detection for some of the deadliest cancers, today announced that its Avantect(R) Multi-Cancer Detection Test was selected for the Vanguard Study ...
MarketWatch

ClearNote Health's Avantect(R) Test Selected for World's Largest Study of Pancreatic Cancer Detection in High-Risk Patient Population

ClearNote Health, a company focused on improving early detection for some of the deadliest cancers, today announced a new collaboration with research teams in Southampton in the United Kingdom.
KXAN

Human Longevity, Inc., Expands Cancer Prevention Offering by Selecting the ClearNote Health Avantect® Early Detection Pancreatic Cancer Test

SOUTH SAN FRANCISCO, Calif., May 6, 2025 /PRNewswire/ -- Human Longevity, Inc. (HLI), the global leader in precision health and longevity medicine, today announced the expansion of its cancer ...
Business Wire

ClearNote Health’s Avantect® Pancreatic Cancer Test Now Available to Health Plan Members Accessing Claritev’s National PPO Networks

SAN DIEGO--(BUSINESS WIRE)--ClearNote Health, a company focused on improving early detection for some of the deadliest cancers, today announced an agreement with Claritev, Inc. (“Claritev”) (NYSE: ...
Business Wire

ClearNote Health’s Avantect® Multi-Cancer Detection Test Selected as One of Two Noninvasive Blood-Based Technologies for National Cancer Institute’s Vanguard Study

SAN DIEGO--(BUSINESS WIRE)--ClearNote Health, a company focused on improving early detection for some of the deadliest cancers, today announced that its Avantect® Multi-Cancer Detection Test was ...